IDYA
IDEAYA Biosciences, Inc.
There isn't enough reported data to score IDYA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IDYA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
IDYA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IDYA PE Valuation
IDYA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IDYA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IDYA's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IDYA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.46 | -$2.54 |
| Q2 2026 | -$1.91 | +$1.94 |
| Q1 2026 | -$1.57 | +$2.08 |
| Q4 2025 | -$1.28 | +$2.08 |
| Q3 2025 | -$1.92 | +$0.40 |
| Q2 2025 | -$3.85 | -$1.67 |
| Q1 2025 | -$3.65 | -$1.65 |
| Q4 2024 | -$3.36 | -$1.40 |
IDYA lost $4.46 per share over the past year, and its loss has widened in each of the last three quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IDYA on earnings quality, reporting a profit while its opponent remains loss making.
IDYA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | -95% |
| Q4 2025 | $10.9M | +55% |
| Q4 2024 | $7M | +78% |
| Q4 2023 | $3.9M | -2.5% |
| Q3 2023 | $8M | -73% |
| Q2 2023 | $3.5M | -39% |
| Q1 2023 | $7.9M | -31% |
| Q4 2022 | $4M | +36% |
IDYA's revenue has slid since its 2025 peak: $10M last quarter, down 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1344% | -1396 points |
| Q2 2026 | -1381% | N/A |
| Q1 2026 | -1655% | N/A |
| Q4 2025 | -870% | +1190 points |
| Q3 2025 | 52% | N/A |
| Q4 2024 | -2059% | -990 points |
| Q4 2023 | -1069% | -411 points |
| Q3 2023 | -417% | -419 points |
IDYA's operating margin was −1344% last quarter, down 1396 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IDYA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IDYA on profitability, with a higher operating margin.
IDYA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.8M | -166% |
| Q2 2026 | -$89.1M | -$25.9M |
| Q1 2026 | -$76.1M | -$14.5M |
| Q4 2025 | -$90.8M | +$31.9M |
| Q3 2025 | $142.2M | +$191.9M |
| Q2 2025 | -$63.1M | -$29.3M |
| Q1 2025 | -$61.7M | -$16.5M |
| Q4 2024 | -$122.8M | -$98.2M |
IDYA has burned cash in almost every quarter: −$350M over the past year, against −$105M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IDYA on cash generation, producing positive trailing cash flow while its opponent burns cash.
IDYA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +12% | +10.9M shares |
| 1 year | +15% | +13.3M shares |
| 3 years | +83% | +46.7M shares |
| 5 years | +213% | +70.1M shares |
| Available history | +408% | +82.7M shares |
IDYA has 103M diluted shares, up 15% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IDYA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IDYA Net Leverage
IDYA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IDYA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 5.8 | Oversold |
IDYA's weekly RSI is 42 (neutral) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IDYA PE vs Healthcare Sector
IDYA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IDYA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 7.5% below |
| 20 week MA | $36.2 | 13% below |
| 50 week MA | $33.8 | 6.7% below |
| 100 week MA | $28.6 | 10% above |
| 200 week MA | $29.5 | 6.6% above |
IDYA has slipped below its 8-, 20- and 50-week averages, though it's still 6.6% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IDYA on trend strength, trading above more of its moving averages.
IDYA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.50 | $12.9 | +52% |
| 2021 | $12.9 | $23.4 | +81% |
| 2022 | $23.4 | $17.0 | -27% |
| 2023 | $17.0 | $35.6 | +109% |
| 2024 | $35.6 | $25.2 | -29% |
| 2025 | $25.2 | $35.2 | +40% |
| 2026 YTD | $35.2 | $31.5 | -11% |
IDYA has finished higher in four of the last six years, three of them by more than 50%. It's down 11% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IDYA on returns for 2026, with the stronger performance.